ZCOR - Zyla Life Sciences

Other OTC - Other OTC Delayed Price. Currency in USD
2.3500
0.0000 (0.00%)
At close: 3:06PM EST
Stock chart is not supported by your current browser
Previous Close2.3500
Open2.3500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.3500 - 2.3500
52 Week Range1.0000 - 3.0500
Volume1,876
Avg. Volume3,096
Market Cap21.998M
Beta (5Y Monthly)N/A
PE Ratio (TTM)1.41
EPS (TTM)1.6660
Earnings DateNov 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
  • Zyla Life Sciences Reports Third Quarter 2019 Financial Results
    PR Newswire

    Zyla Life Sciences Reports Third Quarter 2019 Financial Results

    -- Positive net cash flow of $6.5 million for the quarter ended September 30, 2019 -- -- Net product sales grew to $22.4 million , an increase of 175% over the 2018 third quarter, due to the expanded product ...

  • Zyla Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on November 14, 2019
    PR Newswire

    Zyla Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on November 14, 2019

    WAYNE, Pa., Oct. 31, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a commercial-stage life sciences company focused on marketing treatments for different types of pain and inflammation, today announced that its third quarter 2019 financial results will be released on Thursday, November 14, 2019. Following the announcement, Zyla's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the company's financial and operating results and provide a general business update. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Zyla's website.

  • Zyla Life Sciences Announces Management Changes
    PR Newswire

    Zyla Life Sciences Announces Management Changes

    WAYNE, Pa., Oct. 23, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a commercial-stage life sciences company, today announced that Robert Radie, has resigned as president, chief executive officer and director of the Company to pursue other opportunities. Additionally, the Company announced the appointment of Todd N. Smith as president, chief executive officer and director, effective immediately. "On behalf of the board, I want to thank Bob for his contributions and service to Zyla and its leadership team during the last seven years," said Timothy P. Walbert, chairman of the board, Zyla.

  • Zyla Life Sciences to Present at and Participate in a Panel at the 2019 Disruptive Growth Conference on September 5, 2019
    PR Newswire

    Zyla Life Sciences to Present at and Participate in a Panel at the 2019 Disruptive Growth Conference on September 5, 2019

    WAYNE, Pa., Sept. 3, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a commercial-stage life sciences company, announced that Bob Radie, president and chief executive officer of Zyla, will give a corporate presentation and participate in a panel at the 2019 Disruptive Growth Conference.

  • Zyla Life Sciences Reports Second Quarter 2019 Financial Results
    PR Newswire

    Zyla Life Sciences Reports Second Quarter 2019 Financial Results

    -- First full quarter with seven products drove net product sales to $22.0 million --an increase of 196% from the second quarter 2018 -- -- Net product sales guidance between $80 and $85 million for 2019 ...

  • Zyla Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results on August 13, 2019
    PR Newswire

    Zyla Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results on August 13, 2019

    WAYNE, Pa., July 31, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a commercial-stage life sciences company focused on marketing treatments for different types of pain and inflammation, today announced that its second quarter 2019 financial results will be released on Tuesday, August 13, 2019. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Zyla's website. Zyla Life Sciences is a business committed to bringing important products to patients and healthcare providers.

  • CNW Group

    Growth Public Company Investor Presentations Now Available for On-Demand Viewing

    Growth Public Company Investor Presentations Now Available for On-Demand Viewing

  • Zyla Life Sciences Appoints Dr. Gary M. Phillips to Board of Directors
    PR Newswire

    Zyla Life Sciences Appoints Dr. Gary M. Phillips to Board of Directors

    WAYNE, Pa., June 19, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a growing commercial-stage life sciences company, announced the appointment of Gary M. Phillips, M.D. to its board of directors. "Gary brings to Zyla a wealth of experience from working in the pharmaceutical industry in a range of commercial, business development, strategy and clinical development leadership positions," said Timothy P. Walbert, Zyla chairman of the board and chairman, president and chief executive officer (CEO) of Horizon Therapeutics.

  • CNW Group

    Live Investor Conference & Webinar June 20th

    Live Investor Conference & Webinar June 20th

  • Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer
    PR Newswire

    Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer

    WAYNE, Pa., June 12, 2019 /PRNewswire/ -- Zyla Life Sciences (ZCOR) ("Zyla"), a growing commercial-stage life sciences company, announced the appointment of H. Jeffrey Wilkins, M.D. as senior vice president and chief medical officer (CMO) effective immediately. "With extensive clinical development, medical affairs and product evaluation experience, Dr. Wilkins brings invaluable capabilities as we continue to grow Zyla Life Sciences," said Bob Radie, president and chief executive officer.

  • Egalet Reports First Quarter 2019 Financial Results and Plan to Change Company Name to Zyla Life Sciences
    PR Newswire

    Egalet Reports First Quarter 2019 Financial Results and Plan to Change Company Name to Zyla Life Sciences

    -- Acquisition of five new products completed increasing net product sales to $17.6 million - an increase of more than 100% from the fourth quarter 2018 and 180% from the first quarter 2018 -- -- SG&A ...

  • Egalet to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on May 16, 2019
    PR Newswire

    Egalet to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on May 16, 2019

    WAYNE, Penn., May 14, 2019 /PRNewswire/ -- Egalet Corporation (ZCOR) ("Egalet"), a commercial-stage life sciences company focused on marketing treatments for different types of pain and inflammation, today announced that its first quarter 2019 financial results will be released on Thursday, May 16, 2019. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a commercial-stage life sciences company, is focused on marketing treatments for different types of pain and inflammation.